Other languages Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
20.76 ^USD	-2.67%		-7.49%	+163.12%

13/05	Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	MT
07/05	Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	13/05
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19/03
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia	15/03
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04/03
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise	07/02
Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023	10/12
Jasper Therapeutics Says First Patient Dosed in Phase 1b/2a Trial of Briquilimab for CSU Treatment	30/11
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria	30/11
Jasper Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023	02/11
Jasper Therapeutics, Inc. Announces Board Changes	01/11
Jasper Therapeutics, Inc. Appointed Herb Cross, as Corporate Secretary	25/23/25
Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12
Jasper Therapeutics Strengthens Management Team with Key Appointments	03/23/03
Jasper Therapeutics Reports First Patient Dosed in Phase 1 Trial of Briquilimab	22/23/22
Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome	22/23/22
Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors	20/23/20
Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer	13/23/13
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Other languages

Filters